eli lilly clinical trials tirzepatide Medscape | Retatrutide, Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Company of the Year 2025:

This selectivity arose from structural optimization: removing the central dipeptide from GHRP-1 and using Aib N-terminal substitution to create a selective pentapeptide

No branded GLP-1s (Ozempic, Mounjaro, Wegovy, Zepbound), no oral tablets, no drops, and no microdose options

If youd like some ideas for recipes particularly rich in vitamin B12, check out these meal ideas from Eat This Much

This article covers the exact mechanisms behind peptide stability, reconstitution protocols that preserve maximum potency, dosing schedules that align with biological half-life, and the storage mistakes that silently compromise research outcomes